SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This will be a randomized, double-blind study to evaluate the efficacy, safety, and
pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign
adrenal tumor.